A common theme across the four FDA-approved agents for steroid-refractory chronic GVHD (ibrutinib, belumosudil, ruxolitinib, axatilimab) is a high overall response rate driven primarily by partial remissions. The low rate of complete responses (CRs) highlights a significant unmet need and an opportunity for combination therapies or novel mechanisms.
Despite widespread adoption, post-transplant cyclophosphamide (PTCI) is not the universal standard of care, particularly in myeloablative transplants. Phase 3 trials like PROGRESS-2 failed to show its superiority, leading to continued use of calcineurin inhibitor/methotrexate in nearly half of matched-related donor cases, highlighting a key split in clinical practice.
Trials adding an investigational drug to steroids for initial chronic GVHD treatment consistently fail because many patients respond to steroids alone in the short term. This early efficacy masks the new drug's potential benefit, leading to failed studies (e.g., with mycophenolate, ibrutinib, belumosudil) and a push towards new trial designs.
The AGAVE-201 trial for axatilimab found that a low dose (0.3 mg/kg) given every two weeks was superior to a higher dose given every four weeks. This suggests the drug's mechanism depends on consistent, rather than peak, target inhibition, a key pharmacological insight for future drug development and dosing strategies.
The PRECISION-T trial shows that ORCA-T, a precisely formulated graft with high regulatory T-cell and low conventional T-cell doses, dramatically improves chronic GVHD-free survival by 50 percentage points versus standard of care. This demonstrates that re-engineering the cell graft itself is a powerful prophylactic strategy beyond pharmacological intervention.
Despite being an FDA-approved option, ibrutinib is now rarely used for chronic GVHD. Real-world data reveals lower efficacy than in its pivotal trial (45% vs 60% ORR) and a high rate of discontinuation due to toxicity (42%). This demonstrates how newer agents with better risk-benefit profiles can quickly displace established therapies in clinical practice.